

# Hyperbaric oxygen therapy for post-stroke depression: A systematic review and meta-analysis



Xin-Xin Liang<sup>a,1</sup>, You-guo Hao<sup>b,1</sup>, Xue-ming Duan<sup>a</sup>, Xiu-lan Han<sup>b</sup>, Xiu-xia Cai<sup>c,\*</sup>

<sup>a</sup> Department of Critical Care Medicine, Beihua University Affiliated Hospital, Jilin 132011, China

<sup>b</sup> Department of Rehabilitation, Shanghai Putuo People's Hospital, Shanghai 200060, China

<sup>c</sup> Department of Neurology, Tongchuan City People's Hospital, Shanxi 727000, China

## ARTICLE INFO

### Keywords:

Hyperbaric oxygen  
Post stroke depression  
Adverse events  
Meta-analysis

## ABSTRACT

**Objectives:** Post-stroke depression (PSD) is common consequence of stroke. However, today the majority of PSD patients remains untreated or inadequately treated, especially in the developing countries. Herein, we performed a meta-analysis to evaluate efficacy and safety of hyperbaric oxygen (HBOT) therapy for PSD.

**Patients and methods:** Seven electronic databases were comprehensively searched for randomized clinical trials (RCTs) from inception to May 2019. Outcome measures included response rate, depression severity, neurological deficit, physical disability and adverse events.

**Results:** A total of 27 RCTs involving 2250 participants were identified. Patients in HBOT group had a higher response rate than patients in control group (response rate: 69.4% vs 51.2%, odds ratio [OR] = 2.51, 95% confidence interval [CI] [1.83–3.43],  $P = 0.000$ ). HBOT significantly reduced Hamilton Depression (HAMD) –17 item scores (weighted mean difference [WMD] =  $-4.33$ , 95% CI [ $-4.82$  to  $-3.84$ ],  $P = 0.000$ ), HAMD-24 item scores (WMD =  $-4.31$ , 95% CI [ $-5.01$  to  $-3.62$ ],  $P = 0.000$ ), National Institute of Health Stroke Scale (NIHSS) scores (WMD =  $-2.77$ , 95% CI [ $-3.57$  to  $-1.98$ ],  $P = 0.000$ ), Chinese Stroke Scale (CSS) scores (WMD =  $-3.75$ , 95% CI [ $-5.12$  to  $-2.38$ ],  $P = 0.000$ ) and Modified Scandinavian Stroke Scale (MASS) scores (WMD =  $-3.66$ , 95% CI [ $-6.26$  to  $-1.06$ ],  $P = 0.000$ ). HBOT also improved Barthel Index (WMD = 10.68, 95% CI [7.98–13.37],  $P = 0.000$ ). In subgroup analysis, Group A of studies with hemorrhage patients accounting for less than 20% achieved more reduction of HAMD 17-item score (WMD =  $-4.47$ , 95% CI [ $-5.17$  to  $-3.77$ ],  $P = 0.000$ ) than Group B of studies with hemorrhage patients no less than 20% (WMD =  $-3.73$ , 95% CI [ $-4.20$  to  $-3.26$ ],  $P = 0.000$ ). In addition, patients with HBOT along with antidepressants treatment achieve superior results than patients with antidepressants monotherapy. Patients with HBOT monotherapy achieve a slightly higher response rate than patients with antidepressants monotherapy (OR = 1.29, 95% CI [1.04–1.60],  $P = 0.000$ ). Besides, HBOT group reported less adverse events (9.6% vs 16.6%,  $P < 0.05$ ). The most frequent side-effect of HBOT is ear pain (26 cases).

**Conclusion:** Based on our pooled analysis, HBOT is effective and safe therapeutic approach for PSD. However, results should be cautiously interpreted due to a relatively poor methodological quality.

## 1. Introduction

Stroke is a major cause of disability and mortality worldwide. Post-stroke depression (PSD) is a common psychiatric sequela, which affects around one-third of stroke patients. [1] Main symptoms of PSD were depressive mood, sleep disturbance, decreased energy, guilt and even suicidal tendencies [2,3]. Currently, it is becoming increasingly

accepted that PSD has a strong association with increased mortality, poor life quality, rehabilitation results and functional outcome of stroke survivors [1,4].

Today the majority of PSD patients remains untreated or inadequately treated. [5] Antidepressants (AD) is mainly pharmaceutical treatment for PSD. However, AD is limited by its poor therapeutic effect and increased incidence of adverse events (AEs). A meta-analysis

\* Corresponding author at: Department of Neurology, Tongchuan City People's Hospital, Health Road 172, Wangyi District, Tongchuan City, Shanxi Province 727000, China.

E-mail addresses: [tongtongjun21@163.com](mailto:tongtongjun21@163.com) (X.-X. Liang), [gengjianmei163@163.com](mailto:gengjianmei163@163.com) (Y.-g. Hao), [yinhaojin163@163.com](mailto:yinhaojin163@163.com) (X.-m. Duan), [wangyan96124@163.com](mailto:wangyan96124@163.com) (X.-l. Han), [wanyuanbio@163.com](mailto:wanyuanbio@163.com) (X.-x. Cai).

<sup>1</sup> Xin-xin Liang and You-guo Hao contributed equally to the article.

<https://doi.org/10.1016/j.clineuro.2020.105910>

Received 16 February 2020; Received in revised form 8 May 2020; Accepted 9 May 2020

Available online 16 May 2020

0303-8467/ © 2020 Published by Elsevier B.V.

revealed a high incidence of adverse events in central nervous system and gastrointestinal. [6] A recent RCT showed that fluoxetine, a commonly used AD, increased the frequency of bone fracture [7]. As a complementary therapeutic approach for PSD, nonpharmacological therapy including psychotherapy, repetitive transcranial magnetic stimulation, acupuncture, music intervention and hyperbaric oxygen treatment (HBOT), is increasing [8].

HBOT is a therapy providing patient with 100% pure oxygen at a pressure above normal atmosphere. [9] Currently, HBOT is widely used in patients with diseases involving carbon monoxide poisoning, diabetic foot ulcers, traumatic brain injury and vascular dementia [10–13]. A recent fundamental study by Lim et al. suggested that HBOT attenuated neuroinflammation and inhibited action on serotonin uptake, which has beneficial effect on depression [14]. Several clinical studies also confirmed the effectiveness and safety of HBOT in PSD [15,16]. However, a quantitative analysis of currently available evidence is lacking. Thus, we conduct the first systematic review and meta-analysis to evaluate the efficacy and safety of HBOT for PSD.

## 2. Material and methods

The systematic review and meta-analysis were conducted in accordance with PRISMA checklist [17].

### 2.1. Search strategy

Seven electronic databases (Pubmed, Embase, Cochrane Library, CNKI, VIP, CBM, Wanfang) were comprehensively searched for randomized controlled trials (RCTs) from their inception to May 17, 2019 by two authors independently, with no language restriction. The following terms were used in combination, “hyperbaric oxygen”, “hyperbaric oxygenation”, “HBOT”, “high pressure oxygen”, “post-stroke depression”, “depression after stroke”, “post-ischemic depression”, “depression after cerebral hemorrhage”, “depression after apoplexy”.

### 2.2. Including and excluding criteria

Only RCTs were included in the analysis. Case-control studies, case series and case reports were not considered. All participants were definitely diagnosed with PSD, with no restriction on age, gender, race and severity of disease. Patients in treatment group received HBOT alone or in combination with other therapeutic approaches including AD, psychotherapy, acupuncture and music therapy. Patients in control group received placebo or other treatments except for HBOT. Studies with a retrospective nature, irrelevant topics, no controls, duplicated data or insufficient data were also excluded.

### 2.3. Outcome measures

The primary outcome was response rate, which defined as an over 50% reduction in Hamilton Depression Rating Scale (HAMD) scores after treatment. There are mainly three versions of HAMD (17-, 21-, and 24-item version). Depression severity quantified by HAMD was also considered as primary outcome. The secondary outcome included depression severity quantified by Zung Self-Rating Depression Scale (SDS), neurological deficit quantified by National Institute of Health Stroke Scale (NIHSS), Chinese Stroke Scale (CSS) and Modified Edinburgh-Scandinavian Stroke Scale (MESSS), physical disability determined by Barthel Index (BI), and reported adverse events.

### 2.4. Data extraction

A pre-defined Excel form was used for data collection. Extracted information included the first author's name, year of publication, study period, age, gender, sample size, withdraws, dropouts, interventions, follow-up and outcome measures. We directly contacted the first or

correspondence author by e-mail for insufficient or ambiguous data. Discrepancies were resolved by team discussion.

### 2.5. Methodological quality

Methodological quality was evaluated by Cochrane Collaboration's risk of bias tool [18,19]. Each study was categorized into “low”, “unclear” and “high” risk of bias by two reviewers base on following domains: random sequence generation, allocation concealment, blinding to participants, researchers and outcome evaluators, incomplete data, selective outcome reporting and other sources of bias.

### 2.6. Statistical methods

Statistical analysis was performed by Review Manager 5.0 and STATA 12.0. Dichotomous data was presented as odds ratios (OR) with 95% confidence intervals (CI), while continuous data was presented as weighted mean differences (WMD) with 95% CI. Heterogeneity among studies was assessed by  $I^2$  statistic and Cochrane Q test. A fixed-effect model was utilized for meta-analysis if  $I^2 < 50\%$  or  $P > 0.10$ . Otherwise, a random-effect model was used ( $I^2 > 50\%$  or  $P < 0.10$ ). A univariate meta-regression was conducted to assess the influence of stroke type, does and gender on measured outcomes. A funnel plot and Egger's test was used to assess the publication bias. A sensitivity analysis was performed to explore potential sources of heterogeneity.

## 3. Results

### 3.1. Literature search and study characteristics

Totally 248 articles were identified. We removed 89 duplications and excluded another 89 records after screening the title and abstract. Thus, 70 full-text articles were further assessed for eligibility. As shown in Fig. 1, we excluded studies with irrelevant topics ( $n = 13$ ), reporting inappropriate outcome measures ( $n = 17$ ), not RCTs ( $n = 11$ ), duplicated data ( $n = 8$ ), insufficient data ( $n = 2$ ) and reviews ( $n = 2$ ). Finally, 27 RCTs [15,20–45] involving 2250 participants (1140 in HBOT group and 1110 in control group) were included for meta-analysis. Detailed characteristics of included trials were described in Table 1. All studies were published from 2006 to 2018. The sample size varied from 45 to 200. A total of 22 trials reported diagnostic criteria of depression in accordance with Chinese Classification of Mental Disorders third version (CCMD-3), and 2 studies [38,43] reported criteria of Chinese Classification of Mental Disorders second version (CCMD-2). Depression severity was quantified by HAMD 17-item version in 21 studies, and HAMD 24-item version in 4 studies [15,22,28,30]. All trials reported details of patient selection by CT/MRI evaluations. Sixteen studies reported stroke type of participants but only 2 studies reported location or side of lesions. Among 27 trials, three comparisons were conducted between the treatment group and control group, involving adjuvant HBOT + AD vs. AD (17 studies), HBOT monotherapy vs. AD monotherapy (5 studies) and HBOT + conventional treatment vs. conventional treatment (5 studies). Detailed conventional treatment regimen includes aspirin, mannitol, mecobalamin and calcium channel blockers.

### 3.2. Methodological quality assessment

Methodological quality of included studies was summarized in Fig. 2. Only 8 studies [21,23,24,26,29,31,32,35] described detailed randomization methods. Only 1 study [29] provided information of blinding to participants. Five studies [15,22,28,37,44] provided follow-up data including withdraws and drop outs. None reported allocation concealment. None of studies were at risk of selective outcome reporting. Twenty-five studies reported that HBOT group and control group have comparable baseline data.




Fig. 1. Flowchart of study selection in accordance with PRISMA checklist.

### 3.3. Response rate

Nine studies [15,20–23,25,27,28,30] reported response rate. There was no heterogeneity between studies ( $I^2 = 0$ ,  $P = 0.658$ ), therefore a fixed-effect model was performed. The results indicated that patients in HBOT group had a significantly higher response rate compared with patients in control group (response rate: 69.4%vs51.2%, OR = 2.51, 95% CI [1.83–3.43],  $P = 0.000$ ; Fig. 3).

### 3.4. Effect of HBOT on depression severity

Twenty-five studies employed HAMD scale to evaluate depression severity (21 studies used HAMD 17-items and 4 studies used HAMD 24-items). The results revealed that compared with patients in control group, patients in HBOT group were associated with a more reduced HAMD 17-item scores (WMD =  $-4.33$ , 95% CI [ $-4.82$  to  $-3.84$ ],  $P = 0.000$ ; Fig. 4) and HAMD 24-item scores (WMD =  $-4.31$ , 95% CI [ $-5.01$  to  $-3.62$ ],  $P = 0.000$ ; Fig. 5), respectively. Besides, one study [24] used SDS to assess depression severity. Their results demonstrated that patients in HBOT group had a more reduced SDS scores after rehabilitation treatment ( $P < 0.01$ ).

### 3.5. Effect of HBOT on the level of neurological deficit

Nine studies [15,21–23,31–34,38] assessed patients' neurological deficit by using NIHSS. Compared with patients in control group, patients in HBOT group were associated with a more reduced NIHSS scores (WMD =  $-2.77$ , 95% CI [ $-3.57$  to  $-1.98$ ],  $P = 0.000$ ; Fig. 6), with moderate heterogeneity ( $I^2 = 69.3\%$ ,  $P < 0.01$ ). Four studies [26,40,41,43] used CSS scale, the results indicated that patients in HBOT group were associated with a more reduced CSS scores (WMD =  $-3.75$ , 95% CI [ $-5.12$  to  $-2.38$ ],  $P = 0.000$ ; Fig. 7), with no heterogeneity ( $I^2 = 0$ ,  $P = 0.496$ ). Another three studies [27,37,44] used MESSS scale, HBOT patients were significantly correlated with more reduced MESSS scores (WMD =  $-3.66$ , 95% CI [ $-6.26$  to  $-1.06$ ],  $P = 0.000$ ; Fig. 8), with a high heterogeneity ( $I^2 = 80.0\%$ ,  $P < 0.01$ ).

### 3.6. Effect of HBOT on physical disability

Physical disability was quantified by BI in 11 studies [21,24–27,29,31,32,37,41,44]. Patients in HBOT group were associated with significantly higher BI scores than patients in control group (WMD = 10.68, 95% CI [7.98–13.37],  $P = 0.000$ ; Fig. 9), with a high

**Table 1**  
Baseline characteristics of 27 included studies.

Study ID	Study period	Sample size		Age (years)		CT/MRI evaluation	Hemorrhage event%	Diagnostic criteria	HAMD versions	Intervention		Duration (days)	Outcome measures
		T (M/F)	C (M/F)	T	C					T	C		
Jiao [20]	2016–2017	46 (25/21)	32 (17/15)	54.9 ± 6.5	56.1 ± 5.1	Yes	0%	CCMD-3	17-items	HBOT (70 min, qd, 0.2Mpa) + CT	CT	36	eq \vac(O,1)eq \vac(O,2)
Huang [21]	2014–2016	48 (15/33)	48 (17/31)	51.4 ± 5.4	50.8 ± 5.7	Yes	20.8%	CCMD-3	17-items	HBOT (100 min, qd, 0.2Mpa) + Citalopram (20 mg, qd, PO)	Citalopram (20 mg, qd, PO)	42	eq \vac(O,1)eq \vac(O,2)eq \vac(O,3)eq \vac(O,6)
Lin [22]	2015–2017	56 (32/24)	57 (30/27)	62.0 ± 3.0	64.0 ± 4.0	Yes	-	CCMD-3	24-items	HBOT (70 min, qd, 0.2Mpa)	Fluoxetine (20 mg, qd, PO)	28	eq \vac(O,1)eq \vac(O,2)eq \vac(O,3)eq \vac(O,9)
Chen [23]	2011–2015	30 (12/18)	30 (14/16)	60.7 ± 6.7	62.4 ± 5.9	Yes	45%	CCMD-3	17-items	HBOT (90 min, qd, 0.2Mpa) + Citalopram (20 mg, qd, PO)	Citalopram (20 mg, qd, PO)	60	eq \vac(O,1)eq \vac(O,2)eq \vac(O,3)
Zhu [24]	2013–2015	30 (21/9)	30 (22/8)	57.7 ± 8.6	58.2 ± 9.2	Yes	41.7%	CCMD-3	17-items	HBOT (90 min, qd, 0.12Mpa) + Deaxxit (10.5 mg, bid, PO)	Deaxxit (10.5 mg, bid, PO)	28	eq \vac(O,1)eq \vac(O,2)eq \vac(O,3)eq \vac(O,6)eq \vac(O,8)eq \vac(O,9)
Gao [25]	2011–2015	100 (41/59)	100 (43/57)	62.3 ± 4.2	62.1 ± 4.8	Yes	0%	CCMD-3	17-items	HBOT (60 min, qd, 0.22Mpa) + Deaxxit (10.5 mg, bid, PO)	Deaxxit (10.5 mg, bid, PO)	30	eq \vac(O,1)eq \vac(O,2)eq \vac(O,3)eq \vac(O,6)
Lei [26]	2013–2015	35 (22/13)	35 (20/15)	61.4 ± 9.5	59.7 ± 9.2	Yes	100%	CCMD-3	-	HBOT (110 min, qd, 0.22Mpa) + CT	CT	30	eq \vac(O,1)eq \vac(O,2)eq \vac(O,3)eq \vac(O,4)eq \vac(O,6)
Sun (2015) [27]	2012–2013	68 (-/-)	68 (-/-)	40.3 ± 5.1	40.3 ± 5.1	Yes	-	CCMD-3	-	HBOT (80 min, qd, 0.2Mpa)	Paroxetine (20 mg, qd, PO)	42	eq \vac(O,1)eq \vac(O,2)eq \vac(O,3)eq \vac(O,5)eq \vac(O,6)eq \vac(O,9)
Lin [28]	2013–2014	27 (16/11)	29 (16/14)	61.0 ± 4.0	62.0 ± 5.0	Yes	-	CCMD-3	24-items	HBOT (70 min, qd, 0.2Mpa)	Fluoxetine (20 mg, qd, PO)	28	eq \vac(O,1)eq \vac(O,2)eq \vac(O,3)eq \vac(O,9)
Mao [29]	2012–2013	40 (18/22)	40 (19/21)	55–78	56–78	Yes	0%	CCMD-3	17-items	HBOT (60 min, qd, 0.22Mpa) + Deaxxit (10.5 mg, bid, PO)	Deaxxit (10.5 mg, bid, PO)	30	eq \vac(O,1)eq \vac(O,2)eq \vac(O,3)eq \vac(O,6)eq \vac(O,9)
Hu [30]	2013–2014	30 (12/18)	30 (14/16)	62.1 ± 9.0	62.0 ± 9.7	Yes	28.3%	CCMD-3	24-items	HBOT (120 min, qd, 0.2Mpa) + CT	CT	20	eq \vac(O,1)eq \vac(O,2)eq \vac(O,3)eq \vac(O,7)
Meng [31]	2010–2012	50 (28/22)	50 (26/24)	62.9	63.1	Yes	45%	-	17-items	HBOT (115 min, qd, 0.2Mpa) + Citalopram (20–40 mg, qd, PO)	Citalopram (20–40 mg, qd, PO)	28	eq \vac(O,1)eq \vac(O,2)eq \vac(O,3)eq \vac(O,6)eq \vac(O,9)
Cao [15]	2009–2011	30 (11/19)	30 (12/18)	57 ± 13	56 ± 17	Yes	100%	CCMD-3	24-items	HBOT (80 min, qd, 0.2Mpa) + Deaxxit (10.5 mg, bid, PO)	Deaxxit (10.5 mg, bid, PO)	28	eq \vac(O,1)eq \vac(O,2)eq \vac(O,3)
Liu [32]	2009–2011	48 (31/17)	48 (29/19)	60.0 ± 7.0	60.0 ± 8.0	Yes	47.9%	CCMD-3	17-items	HBOT (90 min, qd, 0.2Mpa) + Sertraline (50–100 mg, qd, PO)	Sertraline (50–100 mg, qd, PO)	28	eq \vac(O,1)eq \vac(O,2)eq \vac(O,3)
Wan [33]	2006–2011	100 (-/-)	90 (-/-)	68.0 ± 7.5	68.0 ± 7.5	Yes	12.5%	CCMD-3	17-items	HBOT (105 min, qd, 0.12Mpa) + Fluoxetine (20 mg, qd, PO)	Fluoxetine (20 mg, qd, PO)	28	eq \vac(O,1)eq \vac(O,2)eq \vac(O,3)
Liu [34]	2009–2011	46 (-/-)	40 (-/-)	64.2 ± 6.8	64.2 ± 6.8	Yes	-	CCMD-3	-	HBOT (90 min, qd, 0.3Mpa) + Duloxetine (60 mg, qd, PO)	Duloxetine (60 mg, qd, PO)	42	eq \vac(O,1)eq \vac(O,2)eq \vac(O,3)eq \vac(O,7)
Li [35]	2011–2012	32 (-/-)	32 (-/-)	60.0 ± 2.0	60.0 ± 2.0	Yes	-	CCMD-3	17-items	HBOT (90 min, qd, 0.2Mpa) + Paroxetine (10–40 mg, qd, PO)	Paroxetine (10–40 mg, qd, PO)	90	eq \vac(O,1)eq \vac(O,2)
Liu [36]	2006–2010	36 (21/15)	36 (23/13)	62.0 ± 9.0	64.0 ± 8.0	Yes	23.6%	CCMD-3	17-items	HBOT (90 min, qd, 0.2Mpa) + Sertraline (50–100 mg, qd, PO)	Sertraline (50–100 mg, qd, PO)	42	eq \vac(O,1)eq \vac(O,2)

(continued on next page)

Table 1 (continued)

Study ID	Study period	Sample size		Age (years)		CT/MRI evaluation	Hemorrhage event%	Diagnostic criteria	HAM-D versions	Intervention			Duration (days)	Outcome measures
		T (M/F)	C (M/F)	T	C					T	C			
Pan [37]	2006–2008	32 (-/-)	32 (-/-)	60.4 ± 8.8	60.4 ± 8.8	Yes	-	CCMD-3	17-items	HBOT (80 min, qd, 0.2Mpa)			42	eq \o\ac(O,2)eq \o\ac(O,5)eq \o\ac(O,6)eq \o\ac(O,9)eq \o\ac(O,2)eq \o\ac(O,3)
Zhao [38]	2004–2008	30 (-/-)	30 (-/-)	61.9 ± 9.9	61.9 ± 9.9	Yes	-	CCMD-2	17-items	HBOT (105 min, qd, 0.12Mpa) + Paroxetine (20 mg, qd, PO)			60	eq \o\ac(O,2)eq \o\ac(O,3)
Liu [39]	2008–2008	22 (15/7)	23 (15/8)	66.2 ± 14	65.8 ± 11	Yes	-	-	17-items	HBOT (100 min, qd, 0.2Mpa) + Antidepressants (no details)			56	eq \o\ac(O,2)
Jiang [40]	2000–2008	42 (26/16)	40 (24/16)	58 ± 19.6	57 ± 18.5	Yes	45.1%	CCMD-3	17-items	HBOT (100 min, qd, 0.16–0.2Mpa) + Fluoxetine (no details)			49	eq \o\ac(O,2)eq \o\ac(O,4)
You [41]	2007–2009	30 (13/17)	30 (15/15)	67.8 ± 8.2	68.5 ± 7.3	Yes	-	CCMD-3	17-items	HBOT (105–115 min, qd, 0.22Mpa) + Deaxxit (10.5 mg, bid, PO)			28	eq \o\ac(O,2)eq \o\ac(O,4)eq \o\ac(O,7)
Wang [42]	2006–2007	32 (-/-)	32 (-/-)	-	-	Yes	-	-	17-items	HBOT (120 min, qd, 0.2Mpa) + CT			30	eq \o\ac(O,2)
Lin [43]	2000–2005	27 (16/11)	25 (14/11)	57 ± 19.2	56 ± 18.1	Yes	40.4%	CCMD-2	17-items	HBOT (90 min, qd, 0.16–0.2Mpa) + Fluoxetine (no details)			49	eq \o\ac(O,2)eq \o\ac(O,4)
Chen [44]	2000–2005	40 (-/-)	40 (-/-)	62.4 ± 9.7	62.4 ± 9.7	Yes	-	CCMD-3	17-items	HBOT (70 min, qd, 0.2 Mpa) + Fluoxetine (20 mg, qd, PO)			60	eq \o\ac(O,2)eq \o\ac(O,5)eq \o\ac(O,6)eq \o\ac(O,9)
Liu [45]	-	33 (19/14)	33 (20/13)	68.9 ± 6.7	62.3 ± 6.4	Yes	27.3%	CCMD-3	17-items	HBOT (115–120 min, qd, 0.2 Mpa) + CT			25	eq \o\ac(O,2)

HBOT: hyperbaric oxygen treatment; CT: conventional treatment (including aspirin, mannitol, mecobalamin and calcium channel blockers); CCMD: Chinese Classification of Mental Disease criteria; Outcome measures: Response rate, HAM-D scores, NIHSS scores, CSS scores, MESSS scores, BI scores, ADL scores, SDS scores, SDS scores, Adverse events.




Fig. 2. Risk of bias evaluation of 27 RCTs: (a) risk of bias graph, (b) risk of bias summary.

heterogeneity ( $I^2 = 90.3\%$ ,  $P < 0.01$ ).

### 3.7. Influence of stroke type

Univariate meta-regression was conducted to assess the influence of stroke type on the outcomes of HBOT treatment. As shown in Table 2, participants with different stroke types achieved significantly different response rate, HAMD-17 score, and BI score after HBOT treatment (all  $P < 0.05$ ). Subsequently we divided all included studies into two subgroups, Group A: studies with hemorrhage patients accounting for less than 20% and Group B: studies with hemorrhage patients accounting for no less than 20%. Subgroup analysis revealed that the effect size was different in two subgroups: Group A (WMD = -4.47, 95% CI [-5.17 to -3.77],  $P < 0.05$ ; Fig. S1) and Group B (WMD = -3.73, 95% CI [-4.20 to -3.26],  $P < 0.05$ ; Fig. S2).

### 3.8. Dose effect

A univariate meta-regression was performed to evaluate the effect of the number and duration time of HBOT treatment. As shown in Table 3, we found the number of HBOT treatment have no effect on response rate, HAMD-17 score, NIHSS score and BI score (all  $P > 0.05$ ). However, the results revealed that the duration time of HBOT treatment

have significant effects on HAMD-17 score, NIHSS score and BI score (all  $P < 0.05$ ), as listed in Table 4.

### 3.9. Gender effect

Meta-regression was conducted to assess the gender effect. As shown in Table 5, no significant associations were found between gender and response rate, HAMD-17 score, NIHSS score or BI score (all  $P > 0.05$ ).

### 3.10. HBOT + antidepressants vs antidepressants

In the pooled analysis, patients receiving HBOT plus antidepressants treatment had a significantly higher response rate compared with patients receiving antidepressants alone (OR = 1.46, 95% CI [1.22–1.74],  $P < 0.01$ ; Fig. 10A). Patients receiving HBOT plus antidepressants also achieved a more reduced HAMD-17 score (WMD = -4.33, 95% CI [-4.70 to -3.97],  $P < 0.01$ ; Fig. 10B), a more reduced NIHSS score (WMD = -2.43, 95% CI [-2.90 to -1.97],  $P < 0.01$ ; Fig. 10C) and a significant higher BI score (WMD = 8.87, 95% CI [7.81–9.93],  $P < 0.01$ ; Fig. 10D).






Fig. 3. Forest plot of response rate.




Fig. 4. Forest plot of HAMD 17-item score.




Fig. 5. Forest plot of HAMD 24-item score.

3.11. HBOT vs. Antidepressants

By pooling a meta-analysis, we found that patients receiving HBOT monotherapy had a slightly higher response rate compared with patients receiving antidepressants monotherapy (OR = 1.29, 95% CI [1.04–1.60], P < 0.01; Fig. 11).

3.12. Adverse events

Seven studies [22,24,27–29,37,44] reported AEs. The incidence of

AEs in HBOT group was lower than that in control group (9.6% vs 16.6%, P < 0.05). The most frequent AEs for HBOT was “ear pain” (26/293) due to barotrauma. No psychological symptoms such as claustrophobia were observed. The main side effects in control group were dizziness (10/296), insomnia (10/296), gastrointestinal disorders (9/296), fatigue (7/296), and moderate headache (6/296).

3.13. Sensitivity analysis and publication bias

We performed a sensitivity analysis for outcomes of response rate,




Fig. 6. Forest plot of NIHSS score.






Fig. 7. Forest plot of CSS score.

HAMD 17-item score, NIHSS score and BI score. As shown in Fig. 12, after removing each study, the pooled results remained stable, indicating the results were reliable and with no potential sources of heterogeneity. In addition, we use Egger’s test to calculate publication bias. As presented in Fig. 13, all  $P > 0.05$  of Egger’s test suggested of no obvious publication bias.

4. Discussion

To our knowledge, this is the first systematic review and meta-analysis to evaluate the efficacy and safety of HBOT for PSD. Pooled results indicated that compared with control group, HBOT group was associated with a higher response rate. HBOT showed beneficial effect on depression severity, neurological deficit, physical disability. Besides, HBOT were associated with less AEs. The most frequent AEs for HBOT is

ear pain due to barotrauma.

HAMD is the most commonly used scale to assess severity of depression [46]. There are three HAMD versions, 17-item, 21-item and 24-item version. In this study, severity of depression was quantified by HAMD 17-item version (in 21 studies) and HAMD 24-item version (in 4 studies). The pooled results suggested that HBOT was associated with more reduced HAMD scores, both in 17-item and 24-item versions, which implied HBOT could effectively alleviate depression symptoms. The mechanisms of HBOT for depression were not fully illuminated. Lim et al. inferred that HBOT affected depression-like behavior by attenuating neuroinflammation and inhibiting action on serotonin uptake [14]. A study by Sumen-Secgin et al. revealed that HBOT reduced the immobility time of rats and displayed an antidepressant-like activity [47]. Consistently, this meta-analysis provided evidence that HBOT could effectively attenuate depression.




Fig. 8. Forest plot of MESSS score.




Fig. 9. Forest plot of BI.

**Table 2**  
Effect of stroke type on HBOT outcomes.

Stroke type	Coef.	t-value	P-value
Response rate	0.14	3.96	0.011
HAMD-17 score	-4.54	-5.15	< 0.01
NIHSS score	-1.99	-0.20	0.848
BI score	3.33	10.25	< 0.01

**Table 3**  
Effect of number of HBOT treatment.

Number of HBOT	Coef.	t-value	P-value
Response rate	0.27	0.03	0.979
HAMD-17 score	-4.25	-0.56	0.584
NIHSS score	-3.09	-0.29	0.779
BI score	10.79	1.10	0.297

**Table 4**  
Effect of duration time of HBOT treatment.

Duration of HBOT	Coef.	t-value	P-value
Response rate	0.28	0.73	0.486
HAMD-17 score	-4.50	-14.25	< 0.01
NIHSS score	-3.34	-6.47	< 0.01
BI score	10.90	6.72	< 0.01

Our meta-analysis also suggested that HBOT patients were associated with a more reduced neurological deficit. In this study, the level of neurological deficit was quantified by three scales, NIHSS, CSS and MESSS. Most of neurologists worldwide use NIHSS scale to assess stroke severity. For PSD patients, a recent study revealed that NIHSS score was an independent risk factor of PSD patients both in acute and chronic


**Table 5**  
Gender effect on HBOT outcome.

Gender effect	Coef.	t-value	P-value
Response rate	0.22	0.01	0.989
HAMD-17 score	-4.32	-0.33	0.748
NIHSS score	-3.22	-0.18	0.866
BI score	11.00	0.68	0.515


stage of stroke [48]. Chinese Stroke Scale, also called CSS, was also an effective method to predict stroke severity of Chinese stroke survivors [49]. Modified Scandinavian stroke scale, also called MESSS, owns its advantages of simplification and less inter-rater variability, which was also widely used in neurological assessment. Consistently, our results indicated that HBOT were associated with a significantly more reduction in either NIHSS score, CSS score and MESSS score, which implied that HBOT could significantly attenuate neurological deficit. Several studies indicated that the level of neurological deficit was closely correlated with PSD development [50,51]. Particularly, stroke itself posed the risk of depression. Thus, HBOT maybe effective to treat PSD via healing neurological disability.

In addition, depression cause a worsen functional outcome and quality of life of stroke patients. Herein, we assessed patients' physical disability by using BI score. The pooled analysis demonstrated that HBOT significantly improved BI scores compared with control group, which implied that HBOT could benefit patients' physical function. Brown et al. suggested that BI measuring functional independence was consistently associated with PSD. Brown C highlighted the importance of helping PSD patients recover as much functional independence as possible in order to improve their life quality. In our analysis, HBOT significantly improve patients' BI scores, thus has a beneficial effect on patients' physical recovery.

This systematic review also assessed the safety of HBOT. The results



**Fig. 10.** Forest plot of (A) response rate; (B) HAMD 17-item score; (C) NIHSS score; (D) BI score with comparison between patients receiving HBOT plus antidepressants and patients receiving antidepressants alone.



**Fig. 11.** Forest plot of response rate with comparison between patients receiving HBOT alone and patients receiving antidepressants alone.

showed that HBOT was associated with less AEs. As we know, a conundrum of AD therapy is its obvious side-effects. Besides, other complementary treatment, including psychotherapy and acupuncture, are largely influenced by a therapist’s experiences, which lead to an uncertain efficacy. This study suggested that HBOT might be a more suitable therapeutic approach for PSD, with advantages of a superior effectiveness and safety.

In this meta-analysis, all included studies reports detailed patient selection by CT/MRI evaluation. Among these, sixteen studies reported stroke type of participants but only 2 studies reported location or side of lesions. By meta-regression analysis, our results revealed that participants with different stroke type achieved different response rate,

HAMD-17 score and BI score after HBOT treatment. Subsequently we divided all included studies into two subgroups, Group A: studies with hemorrhage patients accounting for less than 20% and Group B: studies with hemorrhage patients accounting for no less than 20%. Subgroup analysis showed that the effect size was significantly different in two subgroups. Therefore, we speculate that patients with ischemic stroke may benefit more from HBOT treatment at least in reducing depression symptoms, as subgroup with hemorrhage patients accounting for less than 20% showed a more pronounced effect size of HAMD-17 score reduction. In addition to stroke type, we suggested that CT/MRI evaluation along with baseline HAMD, NIHSS, CSS and BI score altogether used to help patient selection. A study by Hadanny et al. revealed that HBOT induces significant improvements in all cognitive domains. They suggested that the selection of stroke patients for HBOT treatment should be based on functional imaging and baseline cognitive scores, rather than stroke type, location or side of lesion [52,53]. It is a limitation of our study that no functional analysis was described in all included studies. However, according to our meta-analysis, stroke type may be another consideration, which was inconsistent with results by Amir Hadanny et al. Further prospective study should be conducted to explore the effect of stroke type on HBOT outcomes.

The study has several other limitations. First, the methodological quality of included trials was relatively low. Second, most of included studies were with relatively small sample size. Third, we did not assess several laboratory parameters such as serum 5-hydroxytryptamine (5-HT) and norepinephrine (NE), which proven to have closely associations with depression. Forth, the results were largely affected by the subjectivity of outcome assessors in each study, as most outcome measures were based on “scale”.




Fig. 12. Sensitivity analysis of (A) response rate; (B) HAMD 17-item score; (C) NIHSS score; (D) BI score.




Fig. 13. Egger's test of (A) response rate; (B) HAMD 17-item score; (C) NIHSS score; (D) BI score.

### 5. Conclusions

In summary, this meta-analysis indicated that HBOT was associated with a higher response rate, reduced depression severity, attenuated

neurological deficit, improved physical function and less adverse events for PSD patients. HBOT might be an efficacious therapeutic approach for PSD. However, the results should be cautiously interpreted due to relatively poor methodological quality of included studies.

**Research involving human participants and/or animals**

Not applicable.

**Financial funding**

No.

**Compliance with ethical standards**

Disclosure of potential.

**Grant support**

The Key Funding Projects for Independent Innovation of Health System Research in Putuo District, Shanghai, China.

The Research Project on Community Medicine and Health Management of Shanghai Society of Integrated Traditional Chinese and Western (SH201741).

**CRedit authorship contribution statement**

**Xin-Xin Liang:** Data curation, Writing - original draft. **You-guo Hao:** Visualization, Investigation. **Xue-ming Duan:** Supervision, Validation. **Xiu-lan Han:** Methodology, Software, Writing - review & editing. **Xiu-xia Cai:** Conceptualization, Methodology, Software.

**Declaration of Competing Interest**

The authors declare of none of conflict of interest.

**Acknowledgement**

None.

**Appendix A. Supplementary data**

Supplementary material related to this article can be found, in the online version, at doi:<https://doi.org/10.1016/j.clineuro.2020.105910>.

**References**

- [1] R.F. Villa, F. Ferrari, A. Moretti, Post-stroke depression: mechanisms and pharmacological treatment, *Pharmacol. Ther.* 184 (2018) 131–144.
- [2] G. Meng, X. Ma, L. Li, Y. Tan, X. Liu, X. Liu, Y. Zhao, Predictors of early-onset post-ischemic stroke depression: a cross-sectional study, *BMC Neurol.* 17 (1) (2017) 199.
- [3] A. Ypsilanti, L. Lazuras, A. Robson, U. Akram, Anxiety and depression mediate the relationship between self-disgust and insomnia disorder, *Sleep Health* 4 (4) (2018) 349–351.
- [4] R.G. Robinson, R.E. Jorge, Post-stroke depression: a review, *Am. J. Psychiatry* 173 (3) (2016) 221–231.
- [5] S. Paolucci, Advances in antidepressants for treating post-stroke depression, *Expert Opin. Pharmacother.* 18 (10) (2017) 1011–1017.
- [6] M.L. Hackett, C.S. Anderson, A. House, J. Xia, Interventions for treating depression after stroke, *Cochrane Database Syst. Rev.* (4) (2008) CD003437.
- [7] FOCUS Trial Collaboration, Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial, *Lancet.* 393 (10168) (2019) 265–274.
- [8] N.N. Hadidi, R.L. Huna Wagner, R. Lindquist, Nonpharmacological treatments for post-stroke depression: an integrative review of the literature, *Res. Gerontol. Nurs.* 10 (4) (2017) 182–195.
- [9] A.M. Sutherland, H.A. Clarke, J. Katz, R. Katznelson, Hyperbaric oxygen therapy: a new treatment for chronic pain? *Pain Pract.* 16 (5) (2016) 620–628.
- [10] T. Elrajyah, A. Tsapas, G. Prutsky, J.P. Domecq, R. Hasan, B. Firwana, M. Nabhan, L. Prokop, A. Hingorani, P.L. Claus, L.W. Steinkraus, M.H. Murad, A systematic review and meta-analysis of adjunctive therapies in diabetic foot ulcers, *J. Vasc. Surg.* 63 (2 Suppl) (2016) 46S–58S e1-2.
- [11] N.A. Buckley, D.N. Juurlink, G. Isbister, M.H. Bennett, E.J. Lavonas, Hyperbaric oxygen for carbon monoxide poisoning, *Cochrane Database Syst. Rev.* 13 (4) (2011) CD002041.
- [12] F. Wang, Y. Wang, T. Sun, H.L. Yu, Hyperbaric oxygen therapy for the treatment of traumatic brain injury: a meta-analysis, *Neurol. Sci.* 37 (5) (2016) 693–701.
- [13] Q. You, L. Li, S.Q. Xiong, Y.F. Yan, D. Li, N.N. Yan, H.P. Chen, Y.P. Liu, Meta-analysis on the efficacy and safety of hyperbaric oxygen as adjunctive therapy for vascular dementia, *Front. Aging Neurosci.* 11 (2019) 86.
- [14] S.W. Lim, K.C. Sung, Y.L. Shiue, C.C. Wang, C.C. Chio, J.R. Kuo, Hyperbaric oxygen effects on depression-like behavior and neuroinflammation in traumatic brain injury rats, *World Neurosurg.* 100 (2017) 128–137.
- [15] H. Cao, K. Ju, L. Zhong, T. Meng, Efficacy of hyperbaric oxygen treatment of depression in the convalescent stage following cerebral hemorrhage, *Exp. Ther. Med.* 5 (6) (2013) 1609–1612.
- [16] D. Yan, J. Shan, Y. Ze, Z. Xiao-Yan, H. Xiao-Hua, The effects of combined hyperbaric oxygen therapy on patients with post-stroke depression, *J. Phys. Ther. Sci.* 27 (5) (2015) 1295–1297.
- [17] A. Liberati, D.G. Altman, J. Tetzlaff, C. Mulrow, P.C. Gøtzsche, J.P. Ioannidis, M. Clarke, P.J. Devereaux, J. Kleijnen, D. Moher, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration, *PLoS Med.* 6 (7) (2009) e1000100.
- [18] J.P.T. Higgins, S. Green, *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0, The Cochrane Collaboration, Oxford, 2011. (accessed 14 January). <http://www.cochrane.org/handbook>.
- [19] J.P. Higgins, D.G. Altman, P.C. Gøtzsche, P. Jüni, D. Moher, A.D. Oxman, J. Savovic, K.F. Schulz, L. Weeks, J.A. Sterne, Cochrane Bias Methods Group; Cochrane Statistical Methods Group, The Cochrane Collaboration's tool for assessing risk of bias in randomised trials, *BMJ.* 343 (2011) d5928.
- [20] L.Y. Jiao, H.J. Ma, Y.H. Qiu, Clinical observation on hyperbaric oxygen combined with psychological nursing in treating acute cerebral infarction with depression, *Chin. Manip. Rehabil. Med.* 9 (14) (2018) 58–60 (Article in Chinese).
- [21] X.L. Huang, W. Li, H. Qin, Xu Hong Yu XJ, The clinical efficacy of hyperbaric oxygen in the treatment of patients with post stroke depression and its effects on neurologic function, *J. Int. Psychiatry.* 45 (1) (2018) 134–136 140 (Article in Chinese).
- [22] M.J. Lin, Y.X. Shao, R.D. Tang, X.J. Qiu, M.L. You, Clinical observation of acupuncture plus hyperbaric oxygen for depression after cerebral stroke, *Shanghai J. Acu-mox.* 36 (10) (2017) 1173–1176 (Article in Chinese).
- [23] J.Y. Chen, W.M. Ning, Y.R. Zhang, Observation of efficacy of escitalopram in combination with hyperbaric oxygen for treating post stroke depression, *J. Chin. Phys.* 18 (5) (2016) 720–722 (Article in Chinese).
- [24] Z.J. Zhu, Y.M. Hu, A.S. Guo, G.Y. Shen, W.G. Chen, Y. Ren, Clinical observation of hyperbaric oxygen combined with flupentixol and melitracen in the treatment of post-stroke depression, *China Pharmacy.* 27 (35) (2016) 4947–4949 (Article in Chinese).
- [25] Y.J. Gao, S.R. Wei, H.S. Huang, Z. Meng, Clinical observation of effect of hyperbaric oxygen in combination with flupentixol and melitracen on the treatment of depression after cerebral infarction, *J. Bethune Med. Sci.* 14 (1) (2016) 73–74 (Article in Chinese).
- [26] L. Lei, J. Peng, D. Jiang, Effect of HBO assist therapy on serum 5-HT, NE and neural function of the patients with PSD, *J. Mil. Surg. Southwest China.* 18 (6) (2016) 511–514 (Article in Chinese).
- [27] H.M. Sun, Influence of hyperbaric oxygen in combination with psychological intervention on symptom improvement in depression patients after stroke, *J. QiluNurs.* 21 (15) (2015) 47–48 (Article in Chinese).
- [28] M.J. Lin, H.F. Guan, Clinical observation of acupuncture plus hyperbaric oxygen for post-stroke depression, *Shanghai J. Acu-mox.* 34 (6) (2015) 508–510 (Article in Chinese).
- [29] Z.F. Mao, Efficacy observation of hyperbaric oxygen in combination with deanxit on treatment of depression after cerebral infarction, *Chin. J. Mod Drug Appl.* 8 (7) (2014) 138–139 (Article in Chinese).
- [30] Z. Hu, Clinical Study on Hyperbaric Oxygen Combined With Acupuncture Treatment on Post-stroke Depression, *Nanjing University of Chinese Medicine, Nanjing City,* 2014 (Article in Chinese).
- [31] Q.F. Meng, Q.H. Chen, T. Liang, S.S. Sun, Curative effect of hyperbaric oxygen combined with citalopram and massage therapy on post-stroke depression, *Chin. J. Conval. Med.* 22 (15) (2013) 393–395 (Article in Chinese).
- [32] G.H. Liu, L. Cheng, Therapeutic effect of psychological intervention combined with sertraline and hyperbaric oxygen-therapy on patients with post-stroke depression, *Chin. J. Pract. Med.* 39 (5) (2012) 13–15 (Article in Chinese).
- [33] Z.R. Wan, J. Yang, W.H. Jia, L.P. Xu, Clinical efficacy of fluoxetine combined with hyperbaric oxygen on post-stroke depression, *Chin. J. Mult. Organ Dis. Elderl.* 11 (8) (2012) 628–630 (Article in Chinese).
- [34] H.L. Liu, R.X. Zhu, W.L. Yuan, X.X. Sun, G.X. Zhao, Effect of hyperbaric oxygen combined with duloxetine in treatment of post-stroke depression, *Nei Mongol J. Tradit. Chin. Med.* 93 (2012) 110 (Article in Chinese).
- [35] W. Li, Clinical study of hyperbaric oxygen in treating post-stroke depression, *Jilin Med. J.* 33 (15) (2012) 3188–3190 (Article in Chinese).
- [36] X.Y. Liu, S.Y. Wang, J.M. Liu, Efficacy observation of hyperbaric oxygen combined with sertraline on the treatment of post-stroke depression, *Chin. J. Pract. Nerv. Dis.* 14 (7) (2011) 83–84 (Article in Chinese).
- [37] X.B. Pan, H.B. Zhao, Effect of hyperbaric oxygen combined psychological intervention on post-stroke depression, *Mod. J. Integr. Tradit. Chin. West. Med.* 19 (9) (2010) 1054–1055 (Article in Chinese).
- [38] Y. Zhao, L.D. Zhao, W.P. Yang, Effects of hyperbaric oxygen combined paroxetine for treating post-stroke depression in 60 cases, *Mod. Med. Heal.* 26 (24) (2010) 3720–3721 (Article in Chinese).
- [39] C.X. Liu, J.P. Zhang, Effect of psychological intervention combined with hyperbaric oxygen therapy on the quality of life of patients with depression after cerebral stroke, *China Clin. Pract. Med.* 4 (12) (2010) 18–19 (Article in Chinese).
- [40] G.D. Jiang, X. Chen, J.Q. Lin, Analysis for rehabilitation effect of comprehensive

- hyperbaric oxygen treatment on post-stroke depression patients, *Chin. J. Naut Med. Hyperbar Med.* 17 (1) (2010) 58–59 (Article in Chinese).
- [41] Z.J. You, S.H. Zhou, G.M. Xi, Influence of hyperbaric oxygen combined with electroacupuncture on depression and daily function of stroke patients, *Neural In. Funct. Reconstr.* 4 (5) (2009) 375–378 (Article in Chinese).
- [42] X.Y. Wang, W.F. Ding, Therapeutic effect of hyperbaric oxygen on poststroke depression, *Chin. J. Naut Med. Hyperbar Med.* 15 (5) (2008) 299–300 (Article in Chinese).
- [43] J.Q. Lin, A.P. Li, G.L. Li, X.L. Zhang, Effects of hyperbaric oxygen on affection and neurologic function of patients with post-stroke depression, *J. Navy Med.* 28 (1) (2007) 18–20 (Article in Chinese).
- [44] N.T. Chen, H.T. Zhou, Effect of hyperbaric oxygen in treatment of post-stroke depression, *Chongqing Med.* 35 (19) (2006) 1739–1740 (Article in Chinese).
- [45] Y.X. Liu, B.X. Lu, X. Chen, L. Liu, L.N. Hu, Z.W. Yao, Clinical study of hyperbaric oxygen treatment for post-stroke depression, *Guangdong Yi Xue* 27 (8) (2006) 1159–1160 (Article in Chinese).
- [46] S. Obeid, C. Abi Elias Hallit, C. Haddad, Z. Hany, S. Hallit, Validation of the Hamilton Depression Rating Scale (HDRS) and sociodemographic factors associated with Lebanese depressed patients, *Encephale*. 44 (5) (2018) 397–402.
- [47] G. Sumen-Secgin, M. Cimsit, M. Ozek, L. Eroglu, Antidepressant-like effect of hyperbaric oxygen treatment in forced-swimming test in rats, *Methods Find. Exp. Clin. Pharmacol.* 27 (7) (2005) 471–474.
- [48] Z. Wang, M. Zhu, Z. Su, B. Guan, A. Wang, Y. Wang, N. Zhang, C. Wang, Post-stroke depression: different characteristics based on follow-up stage and gender—a cohort perspective study from Mainland China, *Neurol. Res.* 39 (11) (2017) 996–1005.
- [49] X.J. Zhao, Q.X. Li, T.J. Liu, D.L. Wang, Y.C. An, J. Zhang, Y.B. Peng, R.Y. Chen, L.S. Chang, Y. Wang, L. Zhang, H.Y. Fan, X.J. Wang, F.X. Zheng, Predictive values of CSS and NIHSS in the prognosis of patients with acute cerebral infarction: a comparative analysis, *Medicine* 97 (39) (2018) e12419.
- [50] L. Wang, Y. Tao, Y. Chen, H. Wang, H. Zhou, X. Fu, Association of post stroke depression with social factors, insomnia, and neurological status in Chinese elderly population, *Neurol. Sci.* 37 (8) (2016) 1305–1310.
- [51] N. Sun, Q.J. Li, D.M. Lv, J. Man, X.S. Liu, M.L. Sun, A survey on 465 patients with post-stroke depression in China, *Arch. Psychiatr. Nurs.* 28 (6) (2014) 368–371.
- [52] A. Hadanny, M. Rittblat, M. Bitterman, I. May-Raz, G. Suzin, R. Boussi-Gross, Y. Zemel, Y. Bechor, M. Catalogna, S. Efrati, Hyperbaric oxygen therapy improves neurocognitive functions of post-stroke patients - a retrospective analysis, *Restor. Neurol. Neurosci.* 38 (1) (2020) 93–107.
- [53] S. Efrati, E. Ben-Jacob, Reflections on the neurotherapeutic effects of hyperbaric oxygen, *Expert Rev. Neurother.* 14 (3) (2014) 233–236.